Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers
- 1 January 2006
- journal article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 20 (2) , 42-46
- https://doi.org/10.1002/jcla.20102
Abstract
A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC). The results are derived from data collected from January 1998 to October 2003. A total of 210 cancers (approximately 0.3%) were detected, including cancers of the liver, lung, colon, prostate, stomach, pancreas, breast, cervix, ovary, and bladder. Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers. It was surprising to find that many cancers were not detected by their dominant markers but by the elevation of tumor markers not recommended for monitoring their tumor activity. Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage. Screening with multiple tumor markers also allows cancers to be detected in the absence of their dominant markers. If we had not measured the multiple tumor markers, these cancers would have gone undetected.Keywords
This publication has 12 references indexed in Scilit:
- Enthusiasm for Cancer Screening in the United StatesJAMA, 2004
- OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinomaCancer, 2001
- Simultaneous Multianalyte ELISA Performed on a Microarray PlatformClinical Chemistry, 2001
- Array-Based ELISAs for High-Throughput Analysis of Human CytokinesBioTechniques, 2001
- Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.2000
- Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patientsJournal of Clinical Laboratory Analysis, 1998
- CA 125 Elevations in Patients with Malignant LymphomasTumor Biology, 1998
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Expression of monoclonal antibody-defined tumor markers in four carcinomas.1989